The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

Although Novo Nordisk and Eli Lilly are the main players in the GLP-1 arena, a number of other pharmaceutical companies are ...